Review paper: Current strategies in the development of anti-obesity drugs and their safety concerns.
about
Regulation of brown adipocyte metabolism by myostatin/follistatin signalingInhibitors of pancreatic lipase: state of the art and clinical perspectivesComprehensive Map of Molecules Implicated in ObesityDrosophila ste-20 family protein kinase, hippo, modulates fat cell proliferation.Ursolic acid inhibits adipogenesis in 3T3-L1 adipocytes through LKB1/AMPK pathway.The utility of animal models to evaluate novel anti-obesity agents.Obesity pharmacotherapy: current statusEffects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjectsEnzyme-treated Ecklonia cava extract inhibits adipogenesis through the downregulation of C/EBPα in 3T3-L1 adipocytes.The Role of Phospholipase A(2)-derived Mediators in Obesity.Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options.The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation.Therapeutic assessment of cytochrome C for the prevention of obesity through endothelial cell-targeted nanoparticulate system.Oligopeptide complex for targeted non-viral gene delivery to adipocytes.Screening of antidiabetic and antihyperlipidemic potential of oil from Piper longum and piperine with their possible mechanism.Identification of 1H-indene-(1,3,5,6)-tetrol derivatives as potent pancreatic lipase inhibitors using molecular docking and molecular dynamics approach.
P2860
Q26863660-A7858E00-C402-402B-8B5E-A74F148B6477Q27000805-70D7A573-75C7-42B9-BFB3-627FE484AFD5Q28550240-9645953A-E535-427F-88FE-F7334A3F333AQ34700613-345DDB6C-37BB-4EB8-A3D4-6AE72964D2EEQ34906107-A4F60DC8-8F04-4864-9BDE-404B13D60893Q35589958-B1315178-9BAD-4596-BCED-07A97B7904E8Q36341202-AFA9EB6D-92B2-499C-B79A-7B83BEDDE206Q37330686-AAECFF70-7FCA-4BED-9824-74C183981A22Q37714053-F85D3768-CA2F-4470-BB81-78B14FAA3FDDQ37878270-EE92DD92-3043-4A9E-A52E-240A0216A1F3Q38254745-B2F04A3D-8801-4244-8BE8-00B092B27B0EQ38758765-A3E5E7FE-B92B-41EE-B73E-849878DDBE8FQ38818675-F0CAC3F7-5F0C-484F-820C-84E7D3DD1866Q40858515-27904F6C-1453-41D6-8882-C32F7E59C9B3Q41574157-7D845343-C171-45D5-8965-76A6CADCAA7FQ42184688-68CD5D09-0498-44D3-B829-FD82B962BECEQ44320846-92FF04EB-E507-41DC-AE55-AE504A28E01CQ50868368-5FB662C8-E479-47D8-969B-29B5328E0334
P2860
Review paper: Current strategies in the development of anti-obesity drugs and their safety concerns.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Review paper: Current strategi ...... ugs and their safety concerns.
@en
Review paper: Current strategi ...... ugs and their safety concerns.
@nl
type
label
Review paper: Current strategi ...... ugs and their safety concerns.
@en
Review paper: Current strategi ...... ugs and their safety concerns.
@nl
prefLabel
Review paper: Current strategi ...... ugs and their safety concerns.
@en
Review paper: Current strategi ...... ugs and their safety concerns.
@nl
P2860
P356
P1433
P1476
Review paper: Current strategi ...... ugs and their safety concerns.
@en
P2093
C S Elangbam
P2860
P356
10.1354/VP.46-1-10
P577
2009-01-01T00:00:00Z